Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

AI is mapping health stigma faster than it is fixing it

1

Jun 2026

AI is mapping health stigma faster than it is fixing it

This scoping review of 70 studies found that AI is used mainly to detect and measure health-related stigma, rather than to reduce it. Evidence that AI can reduce stigma remains early, limited, and concentrated in mental health conversational-agent studies.

Deep brain stimulation rewires brain circuits linked to depression

1

Jun 2026

Deep brain stimulation rewires brain circuits linked to depression

Researchers from the Icahn School of Medicine at Mount Sinai have uncovered the first direct evidence that deep brain stimulation (DBS) can remodel white matter pathways in the brain and alter communication across large-scale neural networks, revealing a previously unrecognized mechanism that may explain how the therapy helps patients recover from severe depression.

Pediatric experts reveal the 10 research areas set to shape child health

1

Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.